Obesity-Related Cancer Deaths More Than Triple
'Obesity is a well-known risk factor for various cancers, but its contribution to cancer-specific mortality over time hasn't been systematically quantified at a national level,' lead investigator Faizan Ahmed, MD, with Jersey Shore University Medical Center, Neptune City, New Jersey, told Medscape Medical News.
'Clinicians should recognize obesity not just as a cardiovascular or metabolic risk factor but as a significant oncologic concern,' Ahmed said.
He presented his research on July 13 at ENDO 2025, The Endocrine Society Annual Meeting in San Francisco.
Higher Risk for 13 Cancers
According to the CDC, 40% of adults are living with obesity. Obesity is associated with a higher risk for 13 cancers, which make up 40% of all cancers diagnosed in the US each year.
They are adenocarcinoma of the esophagus, postmenopausal breast cancer, as well as cancer of the colon and rectum, uterus, gallbladder, upper stomach, kidneys, liver, ovaries, pancreas, thyroid, meningioma, and multiple myeloma.
To see the trends in obesity-associated cancer deaths over the past two decades, Ahmed and colleagues analyzed CDC data for 33,572 obesity and cancer-related deaths.
They found that the overall age-adjusted mortality rate gradually increased from 3.73 per million in 1999 to 13.52 per million in 2020. 'That's more than a tripling in obesity-related cancer mortality rates over 20 years — a striking rise,' Ahmed told Medscape Medical News .
'To put it in context, this is a steeper increase than seen in many other chronic disease mortality trends during the same time period. It signals a rapidly escalating public health burden,' he noted.
Overall, the average percent change from 2018-2020 was +19.4%. The average annual percentage change was also statistically significant at 5.92 ( P < .000001).
In stratified analyses, the overall age-adjusted mortality rate per million was greater in women than in men (7.22 vs 6.59), in non-Hispanic Black persons than in non-Hispanic White persons (9.20 vs 7.13), and in adults aged 65+ than those aged 25-64 (20.82 vs 3.54).
Age-adjusted mortality rates from obesity-associated cancers were also higher in rural than in urban areas (9.45 vs 6.40).
By region, overall, the Midwest had the highest rates and the Northeast had the lowest rates. State-level analysis revealed that Vermont, Minnesota, and Oklahoma had the highest rates, while Utah, Alabama, and Virginia had the lowest.
Underappreciated Link
The link between obesity and cancer-related mortality is 'often underappreciated,' Ahmed told Medscape Medical News .
'Our findings emphasize the need to prioritize obesity screening and management as part of comprehensive cancer prevention. Counseling patients on weight management should be reframed as a critical component of reducing long-term cancer risk,' he said.
Ahmed also noted that socioeconomic factors could be driving the increase in obesity-related cancer deaths.
'While BMI is a contributing factor, disparities in socioeconomic status, access to preventive care, delays in diagnosis, environmental exposures, and cultural factors likely play a larger role in the observed variations across gender and race.'
'For instance, women may face more delayed diagnoses due to under prioritized symptoms, and certain minority groups may encounter systemic barriers to cancer screening and obesity treatment,' Ahmed said.
To tackle the problem of rising rates of obesity-related cancer deaths, Ahmed said policy initiatives should move from downstream management to upstream prevention.
This would include 'universal access to cancer screening programs, regardless of income or geography; public health campaigns that normalize obesity management as a cancer prevention strategy; policies promoting equitable access to healthy foods, physical activity, and early intervention services; incentives for primary care to integrate weight management into routine visits; and investment in community-based care models targeting underserved populations,' Ahmed told Medscape Medical News .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Next-Generation Sequencing Enhancing Accuracy, Precision Medicine Advancements Propel Growth
The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalence and precision medicine advancements. Key trends include enhanced diagnostic technologies like NGS and PCR, regulatory approvals, and growing targeted therapies demand. Companion Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Companion Diagnostics Market Report and Forecast 2025-2034" report has been added to global companion diagnostics market was valued at USD 7.03 Billion in 2024, driven by the rising prevalence of cancer across the globe. The market is anticipated to grow at a CAGR of 12.50% during the forecast period of 2025-2034 to achieve a value of USD 22.83 Billion by 2034. Companion diagnostic tests help in the diagnosis of diseases and determines the most effective drug for a specific patient. These tests are crucial in cancer treatment, identifying biomarkers that indicate a patient's suitability for individualised treatment. Pharmaceutical companies integrate companion diagnostics into drug development to enhance efficacy, ensuring that only patients most likely to benefit receive targeted global companion diagnostics market is witnessing robust growth due to advancements in precision medicine and increasing demand for targeted therapies. Rising cancer prevalence, the need for biomarker-based diagnostics, and regulatory support for new test approvals drive market expansion. Moreover, the growing adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies further enhances diagnostic accuracy, enabling personalised treatment Drivers and Adoption TrendsThe companion diagnostic market is expanding due to rising demand for precision cancer treatments. Companies like Foundation Medicine lead innovations with products like FOUNDATIONONE CDx, which analyses cancer-related genes in solid tumors. Increasing regulatory approvals and advancements in companion diagnostic tests further support market growth. The rising prevalence of cancer has prompted greater adoption of companion diagnostics, ensuring effective treatment Approvals and COVID-19 ImpactThe U.S. FDA is approving novel companion diagnostic (CDx) tests, such as the Oncomine Dx Target Test by Thermo Fisher Scientific Inc., designed to detect HER2 (ERBB2) activating mutations in non-small cell lung cancer. However, the COVID-19 pandemic initially reduced demand for companion diagnostics products, delaying novel diagnostic tests. Despite this, the global companion diagnostics market is expected to recover and expand significantly during the forecast Companion Diagnostics Market TrendsExpanding IndicationsThe market is broadening beyond oncology to include neurological, cardiovascular, and infectious diseases. Regulatory approvals for new indications enable the development of biomarker-driven therapies, improving patient outcomes. This trend enhances diagnostic applications, supporting pharmaceutical innovations and expanding the market's potential across diverse therapeutic on Precision MedicineThe shift towards precision medicine is driving the demand for companion diagnostics, ensuring targeted drug selection. Advances in genomic profiling allow for personalised treatment plans, reducing adverse reactions and enhancing efficacy. Pharmaceutical companies increasingly integrate biomarker-based diagnostics to develop tailored therapies, improving patient care and optimising treatment Healthcare ExpendituresIncreasing healthcare investments globally support the growth of companion diagnostics, with governments and private entities funding research and development. The demand for early disease detection and advanced diagnostics drives higher spending, ensuring improved diagnostic capabilities and expanding access to innovative treatments, particularly in emerging in TechnologiesCutting-edge technologies like next-generation sequencing (NGS), artificial intelligence (AI), and digital pathology enhance the efficiency of companion diagnostics. Automated platforms enable faster, more accurate biomarker detection, supporting precision medicine. Continuous innovation in diagnostic tools strengthens the market, improving patient outcomes through highly specialised, data-driven Diagnostics Market Growth Factors Rising Cancer Incidence to Drive the Demand for Companion DiagnosticsThe increasing global burden of cancer is a key factor propelling the growth of the companion diagnostics market. According to the American Cancer Society, cancer cases are projected to reach 35 million by 2050, primarily due to population growth and ageing demographics. This surge in cases necessitates advanced diagnostic solutions for early detection, effective treatment, and improved patient outcomes. Companion diagnostics play a crucial role in guiding targeted therapies, ensuring personalised treatment strategies, and enhancing the efficacy of cancer technological advancements such as next-generation sequencing (NGS) and liquid biopsy techniques have further bolstered market expansion. These innovations facilitate rapid genetic profiling, helping oncologists identify specific biomarkers associated with different cancer types. The rising adoption of precision medicine by healthcare providers and pharmaceutical companies is also a significant growth driver. As demand for customised cancer treatments increases, the market for companion diagnostics is expected to expand Approvals for Novel Diagnostic Tests to Fuel Market ExpansionThe approval of new companion diagnostic tests for various indications is another critical factor driving market growth. Regulatory bodies such as the U.S. FDA, European Medicines Agency (EMA), and other global health authorities continue to approve innovative diagnostic solutions for targeted therapies. These approvals validate the clinical efficacy of companion diagnostics, increasing their adoption across healthcare facilities. The expanding pipeline of biomarker-driven therapies further encourages diagnostic companies to develop novel tests, contributing to overall market regulatory support ensures that new diagnostics meet stringent safety and accuracy standards, enhancing physician confidence in their effectiveness. Recent approvals of companion diagnostic assays for lung, breast, and colorectal cancers have provided patients with access to personalised treatment options. As pharmaceutical firms continue to collaborate with diagnostic developers, the market is poised for sustained growth, driven by innovation and regulatory Factors Challenges in Reimbursement Policies and Strict Regulatory Requirements Hindering Market GrowthThe companion diagnostics market faces significant challenges due to complex reimbursement policies. Many healthcare systems lack well-defined reimbursement frameworks for companion diagnostic tests, making it difficult for patients and healthcare providers to afford these tests. The high cost of developing and validating these diagnostics further complicates accessibility, limiting their widespread adoption. Additionally, variations in reimbursement policies across different countries create inconsistencies in market regulatory requirements act as another major barrier, as companion diagnostics must undergo rigorous approval processes to ensure accuracy and efficacy. Regulatory bodies such as the U.S. FDA, EMA, and other global agencies enforce strict guidelines, leading to prolonged approval timelines. Compliance with these complex regulations requires substantial investment and expertise, delaying market entry for new high cost of companion diagnostics is another critical factor restricting market expansion. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies involve expensive equipment and specialised expertise, making these diagnostics unaffordable for many healthcare institutions. The financial burden on smaller laboratories and emerging markets further limits accessibility, restricting the overall growth of the limited awareness and adoption rates in developing regions pose additional challenges. A lack of trained professionals, inadequate infrastructure, and limited integration of precision medicine hinder the widespread implementation of companion diagnostics. Addressing these barriers requires increased investment in education, regulatory simplifications, and improved reimbursement models to unlock the market's full potential. Key Industry Developments In October 2024, Roche secured FDA approval for its VENTANA Claudin 18 (43-14A) RxDx Assay, making it the first immunohistochemistry (IHC) companion diagnostic for CLDN18 protein expression in gastric and gastroesophageal junction adenocarcinoma patients. This breakthrough enabled eligible patients to receive Astellas' targeted therapy VYLOY (zolbetuximab), enhancing treatment precision in gastrointestinal cancers. In August 2024, Illumina, Inc. announced FDA approval of its TruSightT Oncology (TSO) Comprehensive test, a single in vitro diagnostic (IVD) that can profile over 500 genes in solid tumors. This test is designed to identify both adult and pediatric patients with solid tumors that have neurotrophic tyrosine receptor kinase (NTRK) gene fusions. If the test detects this, the patient may benefit from Bayer's VITRAKVI (larotrectinib). The test is also approved for identifying adult patients with advanced or metastatic non-small-cell lung cancer (NSCLC) that has rearranged during transfection (RET) gene fusions. These patients may benefit from treatment with Lilly's RETEVMO (selpercatinib). In August 2024, QIAGEN expanded its collaboration with AstraZeneca to develop companion diagnostics (CDx) for chronic diseases. Using QIAGEN's QIAstat-Dx platform, the partnership aimed at create a genotyping assay that facilitates real-time patient screening, helping healthcare providers determine patient eligibility for AstraZeneca's genomically targeted medicines, ultimately improving treatment accessibility and clinical decision-making. In July 2024, BD and Quest Diagnostics entered a global collaboration to develop flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This partnership aimed at providing an end-to-end CDx solution pharmaceutical companies. It ranged from exploratory panel development to FDA-approved diagnostic kit distribution, so as to advance precision medicine for better treatment selection. Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.03 Billion Forecasted Market Value (USD) by 2034 $22.83 Billion Compound Annual Growth Rate 12.5% Regions Covered Global Supplier Landscape Abbott F. Hoffmann-La Roche Ltd. Agilent Technologies, Inc. Illumina, Inc. Guardant Health Thermo Fisher Scientific Inc. BIOMERIEUX QIAGEN Myriad Genetics, Inc. Global Companion Diagnostics Market SegmentationMarket Breakup by Offerings Products Assays, Kits and Reagents Instruments & Systems Software Services Market Breakup by Technology Polymerase Chain Reaction Immunohistochemistry In Situ Hybridization Next-Generation Sequencing Others Market Breakup by Indication Cancer Neurological Diseases Infectious Diseases Others Market Breakup by End User Pharmaceutical & Biopharmaceutical Companies Reference Laboratories Contract Research Organizations Others Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Companion Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
IRS offers $2.895 million settlement with Maple Lawn over COVID-19 funding
COLDWATER, MI — County owned Maple Lawn Medical Care Facility received written confirmation Tuesday, July 22 of a settlement offer of $2.895 million from the IRS of an appeal of COVID-19 grants owed from the Employee Retention Credit program. Director Jayne Sabaitis told her board July 16 if confirmed, she would accept the offer after appealing denial of the original $3.6 million request filed three years ago during the pandemic. The money will help Maple Lawn make up for its current $1.3 million operating deficit caused by reduction in Medicaid funding for the current federal fiscal year. Prior story Maple Lawn to appeal IRS denial of $3.6 million in COVID-19 relief funds Sabaitis told her board she would consult with accountants Plante-Moran. 'We'll be discussing how that's going to affect our cost report. We want to make sure that we keep our expenses so that our Medicaid rate stays the same to make sure the use of the funds would not hurt next year's Medicaid funding," she said. Sabaitis told the board there are some capital projects which were delayed. 'We're not going to take this money and blow it. We want to hold cash as much as we can' with questions about future funding, she said. Related story With a current $1.2 million loss, Maple Lawn faces concerns with federal Medicaid cuts Sabaitis said five other Michigan nursing homes hired Washington legal counsel to sue the IRS over ERC denial. Maple Lawn was a late applicant for ERC funding only learning near the end of the pandemic the non-profit nursing facilities were eligible. The program was created for eligible businesses and tax-exempt organizations that had employees and saw increased costs or losses affected during the COVID-19 pandemic. Subscribe Support local to the Coldwater Reporter Maple Lawn is licensed for 114 beds but fluctuates by staffing. The nursing care and rehabilitation regularly reports over 90% occupancy. Contact Don Reid: dReid@ This article originally appeared on Coldwater Daily Reporter: Maple Lawn to receive $2.895 million ERC program settlement from IRS Solve the daily Crossword
Fast Company
an hour ago
- Fast Company
I added Bulletproof coffee to the morning routine and loved it
I'm a coffee drinker. Period. It doesn't matter if it's in the waiting area at Jiffy Lube, in the parking lot at Dunkin', or at a vibey Indie mom-and-pop café that harvests their Arabica. If there's hot bean water, I'm having a cup (or three). Obviously, I'd rather my coffee not taste like it's been sitting in a pot for the better part of the day—slightly burnt and watered down. In a perfect world, or in a world with perfect coffee, it should jolt you from grogginess and at the same time, be bursting with flavor. I want my coffee strong and hot (I swear we're still talking about coffee). A dash of milk, too, please. Oh, and I also want my daily morning bev to be undeniably good for me. You can't always have everything when it comes to your morning drink. It's just coffee, after all. It's not a winning lottery ticket or a miracle drug, you know? Bulletproof coffee is seriously upping the bean water game and making me rethink so many hundreds (thousands!?) of subpar slurps. Bulletproof's founder, Dave Asprey, wanted to create a cup of coffee that offers more than a quick jolt of energy. After learning about the benefits of combining caffeine and fat while drinking butter tea in Tibet, he created a brand that would do just that. Bulletproof Coffee, which contains coffee, MCT oil, and grass-fed ghee (clarified butter), was born. Now, arguments have been made over the years (arguments I'll gladly cling to) that coffee, when consumed in moderation, is actually fairly healthy. It may be especially good for heart health. However, Bulletproof coffee attempts to take the 'coffee is healthy' argument to a whole new level. In addition to the Bulletproof butter recipe, the individual flavors have a variety of different ingredients that may offer mind and body benefits, like MCT oil, which is supposed to support focus and mental clarity, and feeling full for longer. Some Bulletproof Coffee flavors have additions like prebiotics, which research has shown can support gut health, along with slippery elm bark, B vitamins, and lion's mane, which has been shown to help with mood. In June the company launched a rebrand, where it introduced two different packaging options—one for its Enhanced line and one for its Artisan line. The Enhanced line is about energy, focus, and gut health and comes in white packaging. The Artisan line features coffee that's focused on taste and clean ingredients, and comes in black packaging. 'This rebrand is about more than just a new look, it's a reflection of where we're headed,' said Andy van Ark, CCO of Bulletproof in a statement. 'We've evolved alongside our consumers, and today's Bulletproof is focused on energizing and empowering consumers to own their day.' In the spirit of owning my day, I tried three different Bulletproof coffees: the Original, the High Achiever from the Enhanced line, and the Mentalist from the Artisan line. First up, was the Original, and it was love at first sip. The flavor is smooth, yet bold and robust. I knew I could spend every morning with this same brew and never get bored. It also seemed to provide steady energy, meaning I felt focused for longer than usual. Next, I sampled the High Achiever, which is especially formulated to help with both energy and focus. I wasn't expecting to notice a huge difference from the Original flavor. But wildly, I felt super focused through my entire work day, and beyond. While I'm usually a three-mugs-a-morning kinda gal, I found myself zipping through work, organizing my office, and only requiring one cup to do it. I mean, I still had two, but I didn't need two. Notably, I didn't hit an afternoon slog, which is pretty common for me after my morning caffeine wears off. Instead, I felt energized all day, which my dog especially appreciated because it meant she got an extra long walk. Last, but definitely not least, came the Mentalist. Like the others, I'd gladly drink this one every day, but in terms of flavor, it was the winner. It has the exact flavor I'm always looking for in a cup of coffee, with hints of cherry, almond, and caramel, and while, no, I didn't pick those all up myself, (I read them on the package), they came together perfectly. Like the original, I felt focused for longer than usual, too. A 12-ounce package of ground coffee runs about $16.99, a bit higher than budget brands, although subscribe and save options on the site can shave off a few dollars. Still, I do think it helped my focus and energy—especially the High Achiever—pretty undeniably. If you're looking for a cup of coffee that tastes really great and has even better body and brain-boosting benefits, I'd recommend not sleeping on Bulletproof. After just one cup, you'll be so full of energy, sleep will be the last thing on your brain anyway.
